Aurelie Rousseau

Gennevilliers, 92230, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Enoxaparin, Tinzaparin, and Apixaban Modulate Cancer Cell Procoagulant Activity and Viability: Comparison with Quercetin.

Enoxaparin, Tinzaparin, and Apixaban Modulate Cancer Cell Procoagulant Activity and Viability: Comparison with Quercetin.

Journal: Cancers

Published: March 15, 2026

The procoagulant signature of cancer cells drives fibrin network formation in tumor microenvironment and impacts its quality. Implications in cancer cell migration and the resistance to anticancer agents.

The procoagulant signature of cancer cells drives fibrin network formation in tumor microenvironment and impacts its quality. Implications in cancer cell migration and the resistance to anticancer agents.

Journal: Thrombosis research

Published: January 16, 2024

The procoagulant phospholipid dependent clotting time and the initiation phase of thrombin generation test are mandatory for the evaluation of the risk for severe early onset preeclampsia.

The procoagulant phospholipid dependent clotting time and the initiation phase of thrombin generation test are mandatory for the evaluation of the risk for severe early onset preeclampsia.

Journal: Thrombosis research

Published: April 30, 2022

Extracellular vesicles derived from pancreatic cancer cells BXPC3 or breast cancer cells MCF7 induce a permanent procoagulant shift to endothelial cells.

Extracellular vesicles derived from pancreatic cancer cells BXPC3 or breast cancer cells MCF7 induce a permanent procoagulant shift to endothelial cells.

Journal: Thrombosis research

Published: January 11, 2019

Procoagulant microparticles derived from cancer cells have determinant role in the hypercoagulable state associated with cancer.

Procoagulant microparticles derived from cancer cells have determinant role in the hypercoagulable state associated with cancer.

Journal: International journal of oncology

Published: June 27, 2017

Differential contribution of tissue factor and Factor XII to thrombin generation triggered by breast and pancreatic cancer cells.

Differential contribution of tissue factor and Factor XII to thrombin generation triggered by breast and pancreatic cancer cells.

Journal: International journal of oncology

Published: April 27, 2017

Cancer cells BXPC3 and MCF7 differentially reverse the inhibition of thrombin generation by apixaban, fondaparinux and enoxaparin.

Cancer cells BXPC3 and MCF7 differentially reverse the inhibition of thrombin generation by apixaban, fondaparinux and enoxaparin.

Journal: Thrombosis research

Published: March 10, 2015

Impact of breast cancer stage, time from diagnosis and chemotherapy on plasma and cellular biomarkers of hypercoagulability.

Impact of breast cancer stage, time from diagnosis and chemotherapy on plasma and cellular biomarkers of hypercoagulability.

Journal: BMC cancer

Published: April 09, 2014

Prevalence of antiphospholipid antibodies in psychiatric patients users and non-users of antipsychotics.

Prevalence of antiphospholipid antibodies in psychiatric patients users and non-users of antipsychotics.

Journal: British journal of haematology

Published: June 25, 2013

Contribution of procoagulant phospholipids, thrombomodulin activity and thrombin generation assays as prognostic factors in intensive care patients with septic and non-septic organ failure.

Contribution of procoagulant phospholipids, thrombomodulin activity and thrombin generation assays as prognostic factors in intensive care patients with septic and non-septic organ failure.

Journal: Clinical chemistry and laboratory medicine

Published: April 26, 2012

Decreased procoagulant phospholipids in patients treated by vitamin K antagonists.

Decreased procoagulant phospholipids in patients treated by vitamin K antagonists.

Journal: Thrombosis research

Published: December 03, 2011

Showing 1-11 of 11

Last Updated: 09/26/2026